COVID-19 vaccine induced interstitial lung disease |
| |
| Affiliation: | 1. Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan;2. Department of Emergency and Critical Care Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan;3. Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan;4. Department of Pediatrics, Tokyo Saiseikai Central Hospital, Tokyo, Japan;5. Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan |
| |
| Abstract: | A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes. |
| |
| Keywords: | COVID-19 vaccine Adverse events Drug-induced interstitial lung disease |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
